Skip to main content
Mirvetuximab Soravtansine-gynx Approved for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lyn Brook
FDA Updates
The FDA has approved mirvetuximab soravtansine-gynx (Elahere™, ImmunoGen, Inc.) for adult patients with folate receptor α (FRα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients are required to have received one to three prior systemic treatment regimens and are selected for treatment based on a...
Pembrolizumab Plus Chemoradiotherapy Approved for FIGO 2014 Stage III-IVA Cervical Cancer
Lyn Brook
FDA Updates
The FDA has granted approval for pembrolizumab (Keytruda®, Merck) with chemoradiotherapy (CRT) for patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage III-IVA cervical cancer. For background: "Pembrolizumab has shown efficacy in patients with cervical cancer," said Domenica Lorusso, MD, PhD, an Associate Professor ...
Dostarlimab-gxly Plus Chemotherapy Approved for dMMR or MSI-H Endometrial Cancer
Keira Smith
FDA Updates
The FDA has approved dostarlimab-gxly (Jemperli®, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab, for patients with mismatch repair–deficient (dMMR) or microsatellite instability­–high (MSI-H) endometrial cancer, as determined by an FDA-approved test. Background: "Dostarlimab is an immune checkpoint inhibitor...
Knowledge Gains for Immunotherapeutic Strategies in Cervical Cancer
Lyn Brook
Practice Patterns
i3 Health has provided an educational activity that has challenged knowledge gaps experienced by the health care team regarding updates on immunotherapeutic strategies for recurrent or metastatic cervical cancer. This continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity, which was presented as bo...
Dostarlimab-gxly Approved For dMMR Endometrial Cancer
Lyn Brook
FDA Updates
The FDA has approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for treatment of mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen or who are not eligible for curative surgery or radiation. Diagnosis is determined by an FDA-approved test. "Endometr...
Mirvetuximab Soravtansine Approved for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
Keira Smith
FDA Updates
The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®, ImmunoGen), a folate receptor alpha (FRα)–directed antibody and microtubule inhibitor conjugate, for patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers previously treated with one to three systemic trea...
Staying Up to Date on Endometrial Cancer With Ritu Salani, MD
Lyn Brook
Expert Analysis
Cancer of the uterine corpus, also called endometrial cancer, is the most common cancer of the female genital tract, with the American Cancer Society estimating that there will be 65,950 new diagnoses and 12,550 fatal cases in the United States in 2022. In this interview, Ritu Salani, MD, Director of the Division of Gynecologic Oncology at the University of California, Los Angeles (UCLA) Health, touches base on a recent activity she led, Emerging Checkpoint Inhibitor-Based Strategies for Advanced Endometrial Cancer. In addition, she discusses updates since recording the activity and why it's important for health care professionals to participate in staying up to date with the evolving landscape of endometrial cancer treatment options.  
FDA Approves Pembrolizumab Combination for Cervical Cancer
Selma Khenissi, MPS
FDA Updates
The FDA has granted approval to pembrolizumab (Keytruda®, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express programmed death-ligand 1 (PD-L1). The FDA has also granted regular approval to single-agent pembrolizumab for patients with recur...
Tisotumab Vedotin Approved for Recurrent/Metastatic Cervical Cancer
Keira Smith
FDA Updates
The FDA has granted accelerated approval to tisotumab vedotin-tftv (TivdakTM, Seagen) for patients with recurrent or metastatic cervical cancer who experience disease progression on or after chemotherapy. "Few effective second-line treatments exist for women with recurrent or metastatic cervical cancer," wrote Robert Coleman, MD, Chief Scientific O...